Published online before print January 28, 2002, doi: 10.1161/hc0802.104283
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:933.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Increased Nitric Oxide Bioavailability in Endothelial Cells Contributes to the Pleiotropic Effect of Cerivastatin
From the Department of Chemistry and Biochemistry, Ohio University, Athens, Ohio.
Correspondence to Dr Tadeusz Malinski, Department of Chemistry and Biochemistry, Ohio University, Athens, OH 45701. E-mail malinski{at}ohio.edu
Background— Although statins preserve endothelial function by reducing serum cholesterol levels, it has been suggested they may also stimulate nitric oxide (NO) synthase in endothelium with concurrent increase in superoxide (O2-) generation, leading to impairment of NO activity. Therefore, measurements of biologically active NO and O2- in endothelium after exposure to the HMG-CoA reductase inhibitor cerivastatin were undertaken to evaluate its potential effect on NO biological activity.
Methods and Results— Highly sensitive electrochemical NO and O2- microsensors were placed near the surface of a single human umbilical vein endothelial cell, and the kinetics of NO and O2- release were recorded in vitro. Cerivastatin demonstrated a time-dependent effect on NO release in endothelial cells. The initial release (approximately the first 3 minutes) was concentration-dependent (0.01 to 10 µmol/L) and was similar to that observed for typical NO synthase agonists calcium ionophore or acetylcholine. Cerivastatin stimulated NO release at a favorable rate and scavenged O2-, which led to the preservation of the active concentration of NO. The sustained effect (after 
6 hours) of cerivastatin on endothelium was associated with an 35% increase in NO release as compared with the initial effect. In contrast to the initial effect, the sustained effect of cerivastatin was shown at concentrations 100-fold lower and was dependent on inhibition of endothelial HMG-CoA reductase.
Conclusions— These data provide direct evidence to prove that in the presence of cerivastatin, the NOS system in endothelium operates with high efficiency toward increasing NO activity by activation of NO release and by concurrent inactivation of O2-.
Key Words: nitric oxide • nitric oxide synthase • endothelium • cholesterol • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  S. Yagi, K.-i. Aihara, Y. Ikeda, Y. Sumitomo, S. Yoshida, T. Ise, T. Iwase, K. Ishikawa, H. Azuma, M. Akaike, et al. Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency Circ. Res., January 4, 2008; 102(1): 68 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Selemidis, G. J. Dusting, H. Peshavariya, B. K. Kemp-Harper, and G. R. Drummond Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells Cardiovasc Res, July 15, 2007; 75(2): 349 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bulhak, J. Roy, U. Hedin, P.-O. Sjoquist, and J. Pernow Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3158 - H3163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Strazzullo, S. M. Kerry, A. Barbato, M. Versiero, L. D'Elia, and F. P. Cappuccio Do Statins Reduce Blood Pressure?: A Meta-Analysis of Randomized, Controlled Trials Hypertension, April 1, 2007; 49(4): 792 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fichtlscherer, C. Schmidt-Lucke, S. Bojunga, L. Rossig, C. Heeschen, S. Dimmeler, and A. M. Zeiher Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy Eur. Heart J., May 2, 2006; 27(10): 1182 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Landmesser, F. Bahlmann, M. Mueller, S. Spiekermann, N. Kirchhoff, S. Schulz, C. Manes, D. Fischer, K. de Groot, D. Fliser, et al. Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans Circulation, May 10, 2005; 111(18): 2356 - 2363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Landmesser, N. Engberding, F. H. Bahlmann, A. Schaefer, A. Wiencke, A. Heineke, S. Spiekermann, D. Hilfiker-Kleiner, C. Templin, D. Kotlarz, et al. Statin-Induced Improvement of Endothelial Progenitor Cell Mobilization, Myocardial Neovascularization, Left Ventricular Function, and Survival After Experimental Myocardial Infarction Requires Endothelial Nitric Oxide Synthase Circulation, October 5, 2004; 110(14): 1933 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Budzyn, P. D. Marley, and C. G. Sobey Chronic mevastatin modulates receptor-dependent vascular contraction in eNOS-deficient mice Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2004; 287(2): R342 - R348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Harris, M. A. Blackstone, S. G. Sood, C. Li, J. M. Goolsby, V. J. Venema, B. E. Kemp, and R. C. Venema Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H560 - H566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Beckman, J. K. Liao, S. Hurley, L. A. Garrett, D. Chui, D. Mitra, and M. A. Creager Atorvastatin Restores Endothelial Function in Normocholesterolemic Smokers Independent of Changes in Low-Density Lipoprotein Circ. Res., July 23, 2004; 95(2): 217 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kalinowski, I. T. Dobrucki, and T. Malinski Race-Specific Differences in Endothelial Function: Predisposition of African Americans to Vascular Diseases Circulation, June 1, 2004; 109(21): 2511 - 2517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wassmann, A. Faul, B. Hennen, B. Scheller, M. Bohm, and G. Nickenig Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function Circ. Res., October 31, 2003; 93 (9): e98 - e103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Walsh, G. Yong, C. Cheetham, G. F. Watts, G. J. O'Driscoll, R. R. Taylor, and D. J. Green Effects of exercise training on conduit and resistance vessel function in treated and untreated hypercholesterolaemic subjects Eur. Heart J., September 2, 2003; 24(18): 1681 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Nangle, M. A. Cotter, and N. E. Cameron Effects of Rosuvastatin on Nitric Oxide-Dependent Function in Aorta and Corpus Cavernosum of Diabetic Mice: Relationship to Cholesterol Biosynthesis Pathway Inhibition and Lipid Lowering Diabetes, September 1, 2003; 52(9): 2396 - 2402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Griffiths, M. A. Sader, M. R. Skilton, J. A. Harmer, and D. S. Celermajer Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease J. Am. Coll. Cardiol., August 20, 2003; 42(4): 698 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Girgis, D. Li, X. Zhan, J. G. N. Garcia, R. M. Tuder, P. M. Hassoun, and R. A. Johns Attenuation of chronic hypoxic pulmonary hypertension by simvastatin Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H938 - H945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kalinowski, L. W. Dobrucki, M. Szczepanska-Konkel, M. Jankowski, L. Martyniec, S. Angielski, and T. Malinski Third-Generation {beta}-Blockers Stimulate Nitric Oxide Release From Endothelial Cells Through ATP Efflux: A Novel Mechanism for Antihypertensive Action Circulation, June 3, 2003; 107(21): 2747 - 2752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kalinowski, T. Matys, E. Chabielska, W. Buczko, and T. Malinski Angiotensin II AT1 Receptor Antagonists Inhibit Platelet Adhesion and Aggregation by Nitric Oxide Release Hypertension, October 1, 2002; 40(4): 521 - 527. [Abstract] [Full Text] [PDF]
|
|